Literature DB >> 16822457

Fanconi anemia.

Grover C Bagby1, Blanche P Alter.   

Abstract

Fanconi anemia (FA) is a rare hereditary disease characterized by bone marrow failure and developmental anomalies; a high incidence of myelodysplasia (MDS), acute nonlymphocytic leukemia (AML), and solid tumors; and cellular hypersensitivity to cross-linking agents. The genetic basis of FA is mutations in any one of the known FA genes. The function of the proteins is largely unknown, but many form complexes with each other, and in one canonical "pathway," eight of the known FA proteins bind together in a complex and monoubiquitinate FANCD2, a protein not present in the core complex. Monoubiquitinated FANCD2 translocates to damage-induced nuclear foci containing BRCA1, BRCA2, and Rad51, thereby protecting the genome. Because hypersensitivity to genotoxic stress is a feature of all somatic cells, this aspect of FA protein function cannot account for the nearly universal development of bone marrow failure. There is strong in vitro and in vivo evidence that at least some of the FA proteins promote survival signaling pathways in hematopoietic cells by forming complexes with signaling molecules. Because associations with heat shock proteins occur in this context, we suggest that these proteins function as co-chaperones and scaffolds that organize proper responses to a wide variety of extracellular cues, some global, and some specific for hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822457     DOI: 10.1053/j.seminhematol.2006.04.005

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  63 in total

1.  Impaired function of Fanconi anemia type C-deficient macrophages.

Authors:  Ying Liu; Kimberly Ballman; Deqiang Li; Shehnaz Khan; Ethel Derr-Yellin; Weinian Shou; Laura S Haneline
Journal:  J Leukoc Biol       Date:  2011-11-21       Impact factor: 4.962

Review 2.  Mechanisms leading to nonrandom, nonhomologous chromosomal translocations in leukemia.

Authors:  Susanne M Gollin
Journal:  Semin Cancer Biol       Date:  2006-10-26       Impact factor: 15.707

3.  Discovering early molecular determinants of leukemogenesis.

Authors:  Grover C Bagby
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

4.  Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice.

Authors:  Yan Li; Wen Xing; Yong-Zheng He; Shi Chen; Steven D Rhodes; Jin Yuan; Yuan Zhou; Jun Shi; Jie Bai; Feng-Kui Zhang; Wei-Ping Yuan; Tao Cheng; Ming-Jiang Xu; Feng-Chun Yang
Journal:  Stem Cell Investig       Date:  2014-10-31

5.  The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks.

Authors:  Jing Huang; Shuo Liu; Marina A Bellani; Arun Kalliat Thazhathveetil; Chen Ling; Johan P de Winter; Yinsheng Wang; Weidong Wang; Michael M Seidman
Journal:  Mol Cell       Date:  2013-10-24       Impact factor: 17.970

6.  Genetic correction of hematopoiesis in Fanconi anemia: the case for a non-HSC-autonomous defect.

Authors:  Amy M Skinner; Peter Kurre
Journal:  Mol Ther       Date:  2009-08       Impact factor: 11.454

7.  Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.

Authors:  Rodrigo T Calado; William T Yewdell; Keisha L Wilkerson; Joshua A Regal; Sachiko Kajigaya; Constantine A Stratakis; Neal S Young
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

8.  Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics.

Authors:  Adina M Cioc; John E Wagner; Margaret L MacMillan; Todd DeFor; Betsy Hirsch
Journal:  Am J Clin Pathol       Date:  2010-01       Impact factor: 2.493

Review 9.  DNA damage response, redox status and hematopoiesis.

Authors:  Cary N Weiss; Keisuke Ito
Journal:  Blood Cells Mol Dis       Date:  2013-09-13       Impact factor: 3.039

10.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Authors:  P S Becker; J A Taylor; G D Trobridge; X Zhao; B C Beard; S Chien; J Adair; D B Kohn; J E Wagner; A Shimamura; H-P Kiem
Journal:  Gene Ther       Date:  2010-05-20       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.